Natco Pharma Q2 Profit Surges 83%, Declares Interim Dividend

Natco Pharma Ltd. posted strong growth in Q2 results, with net profit increasing by 83% year-on-year to ₹676.5 crore, compared to ₹369 crore in the same quarter of the previous year.

The revenue for the September quarter rose by 33% to ₹1,371 crore from ₹1,031 crore in the corresponding period last year. The company’s EBITDA jumped 75.7% year-on-year to ₹804.2 crore, while EBITDA margin improved to 58.66%, up from 44.40% in the same period last year, driven by solid gRevlimid performance.

Growth in export formulations and stable domestic pharma operations contributed significantly to Natco’s quarterly performance. Natco Pharma’s board declared a second interim dividend of ₹1.50 per equity share, with a face value of ₹2, for FY 2024-25. The record date for the interim dividend is set for November 25, 2024, with payment scheduled by December 2, 2024.